{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:18:07Z","timestamp":1793765887389,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03528-5","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:47:49Z","timestamp":1744285669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study"],"prefix":"10.1186","volume":"27","author":[{"given":"Andrew","family":"\u00d6st\u00f6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rebella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaie","family":"Namas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"McDearmon-Blondell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lagunes-Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Strengholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devy","family":"Zisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"3528_CR1","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","volume":"30","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30:779\u201387.","journal-title":"Mod Rheumatol"},{"key":"3528_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133\u201345.","journal-title":"Nat Rev Rheumatol"},{"key":"3528_CR3","doi-asserted-by":"publisher","first-page":"e003196","DOI":"10.1136\/rmdopen-2023-003196","volume":"9","author":"MA Messelink","year":"2023","unstructured":"Messelink MA, den Broeder AA, Marinelli FE, Michgels E, Verschueren P, Aletaha D, et al. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD Open. 2023;9:e003196.","journal-title":"RMD Open"},{"key":"3528_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36:685\u201395.","journal-title":"Rheumatol Int"},{"key":"3528_CR5","first-page":"69","volume":"34","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2016. Clin Exp Rheumatol. 2016;34:69\u201376.","journal-title":"Clin Exp Rheumatol"},{"key":"3528_CR6","doi-asserted-by":"publisher","first-page":"755844","DOI":"10.3389\/fimmu.2021.755844","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844.","journal-title":"Front Immunol"},{"key":"3528_CR7","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.autrev.2017.10.002","volume":"16","author":"EG Favalli","year":"2017","unstructured":"Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R. The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev. 2017;16:1185\u201395.","journal-title":"Autoimmun Rev"},{"key":"3528_CR8","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.2174\/1381612821666150310145758","volume":"21","author":"E Astorri","year":"2015","unstructured":"Astorri E, Nerviani A, Bombardieri M, Pitzalis C. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology. Curr Pharm Des. 2015;21:2216\u201324.","journal-title":"Curr Pharm Des"},{"key":"3528_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"3528_CR10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3528_CR11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"3528_CR12","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511\u201321.","journal-title":"N Engl J Med"},{"key":"3528_CR13","doi-asserted-by":"publisher","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","volume":"8","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open. 2022;8:e002012.","journal-title":"RMD Open"},{"key":"3528_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol"},{"key":"3528_CR15","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788\u2013800.","journal-title":"Arthritis Rheumatol"},{"key":"3528_CR16","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503\u201312.","journal-title":"Lancet"},{"key":"3528_CR17","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303\u201311.","journal-title":"Lancet"},{"key":"3528_CR18","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed MF, Chen S, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72:1607\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"3528_CR19","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513\u201324.","journal-title":"Lancet"},{"key":"3528_CR20","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9:e002735.","journal-title":"RMD Open"},{"key":"3528_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021;80:304\u201311.","journal-title":"Ann Rheum Dis"},{"key":"3528_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","volume":"57","author":"G Kilcher","year":"2018","unstructured":"Kilcher G, Hummel N, Didden EM, Egger M, Reichenbach S. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. Rheumatology (Oxford). 2018;57:354\u201369.","journal-title":"Rheumatology (Oxford)"},{"key":"3528_CR23","unstructured":"RINVOQ\u00ae (upadacitinib). US prescribing information. 2019. Available from: Accessed September 2024. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf"},{"key":"3528_CR24","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","volume":"12","author":"JP Vandenbroucke","year":"2014","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12:1500\u201324.","journal-title":"Int J Surg"},{"key":"3528_CR25","unstructured":"Medical Dictionary For Regulatory Activities (MedDRA). What\u2019s new MedDRA version 26.0. 2023. Available from: Accessed September 2024. https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/whatsnew_26_0_English.pdf"},{"key":"3528_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.reuma.2021.08.001","volume":"18","author":"R Gonz\u00e1lez Mazar\u00edo","year":"2022","unstructured":"Gonz\u00e1lez Mazar\u00edo R, Frag\u00edo Gil JJ, Ivorra Cort\u00e9s J, Grau Garc\u00eda E, Ca\u00f1ada Mart\u00ednez AJ, Gonz\u00e1lez Puig L, et al. Real-world effectiveness and safety of JAK inhibitors in rheumatoid arthritis: a single-centre study. Reumatol Clin (Engl Ed). 2022;18:523\u201330.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"3528_CR27","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1093\/rheumatology\/keaa858","volume":"60","author":"J Fitton","year":"2021","unstructured":"Fitton J, Melville AR, Emery P, Nam JL, Buch MH. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. Rheumatology (Oxford). 2021;60:4048\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"3528_CR28","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1136\/annrheumdis-2023-eular.1326","volume":"82","author":"DC Diederik","year":"2023","unstructured":"Diederik DC, Durez P, Lenaerts J, Westhovens R, Verschueren P. AB0421\u2005real-world effectiveness of upadacitinib in patients with rheumatoid arthritis. Ann Rheum Dis. 2023;82:1398\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3528_CR29","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/annrheumdis-2023-eular.705","volume":"82","author":"K Biddle","year":"2023","unstructured":"Biddle K, Buckeldee O, Latheef A, Al-Shakarchi I, Sofat N. AB0450\u2005real-world use of JAK inhibitors in rheumatological practice in South London. Ann Rheum Dis. 2023;82:1414\u20135.","journal-title":"Ann Rheum Dis"},{"key":"3528_CR30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/annrheumdis-2020-218412","volume":"80","author":"RM Fleischmann","year":"2021","unstructured":"Fleischmann RM, Blanco R, Hall S, Thomson GTD, Van den Bosch FE, Zerbini C, et al. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80:432\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3528_CR31","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","volume":"78","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78:1454\u201362.","journal-title":"Ann Rheum Dis"},{"key":"3528_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40744-024-00658-1","volume":"11","author":"R Fleischmann","year":"2024","unstructured":"Fleischmann R, Blanco R, Van den Bosch F, Bessette L, Song Y, Penn SK, et al. Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-year data from SELECT-COMPARE. Rheumatol Ther. 2024;11:599\u2013615.","journal-title":"Rheumatol Ther"},{"key":"3528_CR33","unstructured":"Haaland D, Chan J, Lisnevskaia L, Chow A, Girard T, Fournier P et al. Effectiveness of upadacitinib in patients with rheumatoid arthritis in Canadian real-world practice: interim results from the CLOSE-UP Post-Marketing Observational Study [abstract]. Arthritis Rheumatol. 2022; 74(Suppl 9). Available from: https:\/\/acrabstracts.org\/abstract\/effectiveness-of-upadacitinib-in-patients-with-rheumatoid-arthritis-in-canadian-real-world-practice-interim-results-from-the-close-up-post-marketing-observational-study\/. Accessed September 2024."},{"key":"3528_CR34","first-page":"726","volume":"42","author":"T Witte","year":"2024","unstructured":"Witte T, Kiltz U, Haas F, Riechers E, Prothmann U, Adolf D, et al. The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study. Clin Exp Rheumatol. 2024;42:726\u201335.","journal-title":"Clin Exp Rheumatol"},{"key":"3528_CR35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40744-024-00651-8","volume":"11","author":"L Bessette","year":"2024","unstructured":"Bessette L, Chan J, Chow A, Lisnevskaia L, Richard N, Fournier PA, et al. Real-world effectiveness of upadacitinib for treatment of rheumatoid arthritis in Canadian patients: interim results from the prospective observational CLOSE-UP study. Rheumatol Ther. 2024;11:563\u201382.","journal-title":"Rheumatol Ther"},{"key":"3528_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","volume":"44","author":"PG Conaghan","year":"2021","unstructured":"Conaghan PG, Mysler E, Tanaka Y, Da Silva-Tillmann B, Shaw T, Liu J, et al. Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program. Drug Saf. 2021;44:515\u201330.","journal-title":"Drug Saf"},{"key":"3528_CR37","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/jcm12051734","volume":"12","author":"R Sanmart\u00ed","year":"2023","unstructured":"Sanmart\u00ed R, Corominas H. Upadacitinib for patients with rheumatoid arthritis: a comprehensive review. J Clin Med. 2023;12:1734.","journal-title":"J Clin Med"},{"key":"3528_CR38","doi-asserted-by":"publisher","first-page":"e31161","DOI":"10.1097\/MD.0000000000031161","volume":"101","author":"J Temmoku","year":"2022","unstructured":"Temmoku J, Migita K, Yoshida S, Matsumoto H, Fujita Y, Matsuoka N, et al. Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis. Med (Baltim). 2022;101:e31161.","journal-title":"Med (Baltim)"},{"key":"3528_CR39","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40744-023-00594-6","volume":"10","author":"LR Harrold","year":"2023","unstructured":"Harrold LR, Zueger P, Nowell WB, Blachley T, Schrader A, Lakin PR, et al. A real-world effectiveness study using a mobile application to evaluate early outcomes with upadacitinib in rheumatoid arthritis. Rheumatol Ther. 2023;10:1519\u201333.","journal-title":"Rheumatol Ther"},{"key":"3528_CR40","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1136\/annrheumdis-2023-eular.1902","volume":"82","author":"M Kamiya","year":"2023","unstructured":"Kamiya M, Mori S, Yamazaki K, Oka N, Shoukaku N, Togawa D. AB0474\u2005real-world single center use of upadacitinib in rheumatoid arthritis patients, including those refractory to first-generation JAK inhibitors. Ann Rheum Dis. 2023;82:1430.","journal-title":"Ann Rheum Dis"},{"key":"3528_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40744-024-00639-4","volume":"11","author":"JF Baker","year":"2024","unstructured":"Baker JF, Zueger P, Ali M, Bennett D, Yu M, Munoz Maldonado Y, et al. Real-world use and effectiveness outcomes in patients with rheumatoid arthritis treated with upadacitinib: an analysis from the CorEvitas Registry. Rheumatol Ther. 2024;11:363\u201380.","journal-title":"Rheumatol Ther"},{"key":"3528_CR42","first-page":"485","volume":"37","author":"R Caporali","year":"2019","unstructured":"Caporali R, Zavaglia D. Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37:485\u201395.","journal-title":"Clin Exp Rheumatol"},{"key":"3528_CR43","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/jcm8101548","volume":"8","author":"RB Mueller","year":"2019","unstructured":"Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M, Souza A, et al. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. J Clin Med. 2019;8:1548.","journal-title":"J Clin Med"},{"key":"3528_CR44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41598-023-50379-8","volume":"14","author":"C Martinez-Molina","year":"2024","unstructured":"Martinez-Molina C, Gich I, Diaz-Torn\u00e9 C, Park HS, Feliu A, Vidal S, et al. Patient-related factors influencing the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: a real-world study. Sci Rep. 2024;14:172.","journal-title":"Sci Rep"},{"key":"3528_CR45","first-page":"kead543","volume":"1","author":"S Hayashi","year":"2023","unstructured":"Hayashi S, Tachibana S, Maeda T, Yamashita M, Shirasugi I, Yamamoto Y, et al. Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Rheumatology (Oxford). Nov 2023;1:kead543.","journal-title":"Rheumatology (Oxford)"},{"key":"3528_CR46","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1007\/s12325-023-02619-6","volume":"40","author":"M Bergman","year":"2023","unstructured":"Bergman M, Chen N, Thielen R, Zueger P. One-year medication adherence and persistence in rheumatoid arthritis in clinical practice: a retrospective analysis of upadacitinib, adalimumab, baricitinib, and tofacitinib. Adv Ther. 2023;40:4493\u2013503.","journal-title":"Adv Ther"},{"key":"3528_CR47","doi-asserted-by":"publisher","first-page":"e003392","DOI":"10.1136\/rmdopen-2023-003392","volume":"9","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, et al. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023;9:e003392.","journal-title":"RMD Open"},{"key":"3528_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/ph15010048","volume":"15","author":"M Alexander","year":"2021","unstructured":"Alexander M, Luo Y, Raimondi G, O\u2019Shea JJ, Gadina M. Jakinibs of all trades: inhibiting cytokine signaling in immune-mediated pathologies. Pharmaceuticals (Basel). 2021;15:48.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3528_CR49","unstructured":"Lanzillotta M, Boffini N, Barone E, Cincinelli G, Gerardi MC, Luciano N, et al. Safety of Janus kinase inhibitors: a real-world multicenter retrospective cohort study. J Rheumatol 2023;Aug 1:jrheum2023\u20130145."},{"key":"3528_CR50","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/joim.13681","volume":"294","author":"X Tong","year":"2023","unstructured":"Tong X, Shen CY, Jeon HL, Li Y, Shin JY, Chan SC, et al. Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: a multi-centre cohort study. J Intern Med. 2023;294:314\u201325.","journal-title":"J Intern Med"},{"key":"3528_CR51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/kead163","volume":"63","author":"R Westermann","year":"2024","unstructured":"Westermann R, Cordtz RL, Duch K, Mellemkjaer L, Hetland ML, Burden AM, et al. Cancer risk in patients with rheumatoid arthritis treated with Janus kinase inhibitors: a nationwide Danish register-based cohort study. Rheumatology (Oxford). 2024;63:93\u2013102.","journal-title":"Rheumatology (Oxford)"},{"key":"3528_CR52","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/ard-2022-223636","volume":"82","author":"V Huss","year":"2023","unstructured":"Huss V, Bower H, Hellgren K, Frisell T, Askling J. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis. 2023;82:911\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3528_CR53","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40744-023-00557-x","volume":"10","author":"A Kivitz","year":"2023","unstructured":"Kivitz A, Wells AF, Vargas JI, Baraf HSB, Rischmueller M, Klaff J, et al. Long-term efficacy and safety of upadacitinib in patients with rheumatoid arthritis: final results from the BALANCE-EXTEND open-label extension study. Rheumatol Ther. 2023;10:901\u201315.","journal-title":"Rheumatol Ther"},{"key":"3528_CR54","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/rheumatology\/keu334","volume":"54","author":"JW Jacobs","year":"2015","unstructured":"Jacobs JW, Ten Cate DF, van Laar JM. Monitoring of rheumatoid arthritis disease activity in individual patients: still a hurdle when implementing the treat-to-target principle in daily clinical practice. Rheumatology (Oxford). 2015;54:959\u201361.","journal-title":"Rheumatology (Oxford)"},{"key":"3528_CR55","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/diagnostics12010182","volume":"12","author":"B Frade-Sosa","year":"2022","unstructured":"Frade-Sosa B, Ponce A, Ruiz-Esquide V, Garc\u00eda-Y\u00e9benes MJ, Morl\u00e1 R, Sapena N, et al. High sensitivity C reactive protein in patients with rheumatoid arthritis treated with antibodies against IL-6 or JAK inhibitors: a clinical and ultrasonographic study. Diagnostics (Basel). 2022;12:182.","journal-title":"Diagnostics (Basel)"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03528-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03528-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03528-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:02:34Z","timestamp":1744329754000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03528-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3528"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03528-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the International Council on Harmonisation guidelines and the Declaration of Helsinki. The trial protocol was approved by independent ethics committees and institutional review boards. Written informed consent was provided by patients ahead of study screening.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AO has served as a consultant and\/or on advisory boards and\/or undertaken clinical trials for AbbVie, GSK, Janssen, Lilly, Novartis, and Pfizer. EF has received honoraria and research grants from AbbVie, BMS, Galapagos, Lilly, MSD, Novartis, Pfizer, Roche, and Sobi. PS has received honoraria and research grants from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB through the University of Crete Special Account for Research. JA has received honoraria from AbbVie, AstraZeneca, Biogen, BMS, Fresenius Kabi, Galapagos, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche-Chugai, Sandoz, and Sanofi; and research grants from BMS, Fresenius Kabi, Galapagos, Novartis (Dreamer), and Pfizer (Passerelle). MR has received honoraria and\/or support to participate in academic events from AbbVie, Bayer, Pfizer, and Roche. RN has no conflicts of interest to declare. EMB, TG, ILG, and SS are AbbVie employees and may own AbbVie stock or options. DZ has received speaker fees and\/or advisory honoraria from AbbVie, AstraZeneca, GSK, Janssen, Lilly, Novartis, Pfizer, Roche, and Sandoz, and research grants from Pfizer. SA has received speaker fees, research grants, and advisory honoraria from AbbVie, Amgen, AstraZeneca, BMS, Gilead, GSK, Hikma, Janssen, Lilly, Novartis, Organon, Pfizer, Roche, Sandoz, Sanofi, and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}